Avanos Medical, Inc.
AVNS
$13.11
-$0.01-0.08%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.95% | 2.70% | 1.48% | 1.34% | 2.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.95% | 2.70% | 1.48% | 1.34% | 2.15% |
| Cost of Revenue | 13.31% | 10.16% | 6.04% | 5.35% | 4.39% |
| Gross Profit | -7.19% | -3.28% | -2.13% | -1.77% | 0.42% |
| SG&A Expenses | -1.66% | 2.26% | 1.52% | -2.93% | -2.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -110.53% | 14.81% | -95.35% | -13.04% | 15.15% |
| Total Operating Expenses | 4.63% | 5.44% | 2.77% | 0.70% | 0.63% |
| Operating Income | -50.00% | -40.94% | -17.72% | 13.33% | 44.44% |
| Income Before Tax | 83.59% | -1,969.35% | -3,508.57% | -14,733.33% | -5,005.06% |
| Income Tax Expenses | 139.41% | -538.64% | -327.14% | -446.51% | -950.00% |
| Earnings from Continuing Operations | 81.13% | -2,259.45% | -6,690.00% | -23,662.50% | -3,802.02% |
| Earnings from Discontinued Operations | -- | 95.00% | -371.43% | 92.74% | 88.82% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.41% | -3,086.62% | -6,115.58% | -518.33% | -534.47% |
| EBIT | -50.00% | -40.94% | -17.72% | 13.33% | 44.44% |
| EBITDA | -29.63% | -25.87% | -9.12% | 7.12% | 18.54% |
| EPS Basic | 81.54% | -3,090.51% | -6,091.07% | -530.36% | -546.92% |
| Normalized Basic EPS | -54.11% | -43.75% | -15.26% | 49.13% | 137.12% |
| EPS Diluted | 81.51% | -3,197.02% | -6,306.59% | -530.44% | -545.74% |
| Normalized Diluted EPS | -54.32% | -43.64% | -15.57% | 48.66% | 138.00% |
| Average Basic Shares Outstanding | 0.60% | 0.27% | -0.38% | -1.08% | -1.23% |
| Average Diluted Shares Outstanding | 0.16% | -0.38% | -0.38% | -0.64% | -0.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |